Focused on muscle and
positioned for growth

Investors & Media

Dyne Therapeutics is building a leading muscle disease company dedicated to advancing innovative life-transforming therapeutics for people living with genetically driven diseases. With its proprietary FORCE™ platform, Dyne is developing modern oligonucleotide therapeutics that are designed to overcome limitations in delivery to muscle tissue seen with other approaches. Dyne's broad portfolio of therapeutic candidates for serious muscle diseases includes programs in myotonic dystrophy type 1 (DM1), Duchenne muscular dystrophy (DMD) and facioscapulohumeral muscular dystrophy (FSHD).

Stock information

Stock is

Data Provided by Refinitiv.

Minimum 15 minutes delayed.

Events

No events scheduled

btn Events

Investor contact

Contact Dyne investor relations at ir@dyne-tx.com

contact